Q-omics provides the consensus-scored LINC01564 profile across patient tissues and cancer cell-line models. LINC01564 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LINC01564 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, LINC01564 RNA expression shows 12,067 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, LUAD, and TGCT as cancer lineages where LINC01564 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01564 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01564 survival associations across molecular data types. LINC01564 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01564 RNA expression–survival associations across cancer types. High LINC01564 expression shows unfavorable associations in STAD, UCEC and UVM, but favorable associations in BLCA, MESO and OV. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for LINC01564 RNA expression.
This table summarizes LINC01564 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01564. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01564 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in LUAD, HNSC and LUSC. The LUAD box plot shows higher LINC01564 RNA expression in tumor versus normal tissue (log2 FC = +1.020, t-test p < 0.001).
This table shows molecular features associated with LINC01564 in patient tissues and cancer cell lines. In patient samples, LINC01564 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
